FDA Approves SKYRIZI Product Under Rare Pediatric Disease Priority Review Voucher

Summary

The FDA has approved a product redeeming a priority review voucher for SKYRIZI, a treatment for a rare pediatric disease, following a review of its supplemental application submitted on June 16, 2022.